Aphton Corp. said Tuesday that its gastrin immunogen was welltolerated in the initial safety phase of its clinical trial for colorectalcancer treatment.The Woodland, Calif., company said the unnamed immunogen resultedin the production of antibody titers in excess of circulatory gastrin 17(G17) levels, thus ensuring the complete neutralization of G17 andreduction of stomach acid by 90 percent in all assayed patients.Aphton hopes to start the dose-ranging phase of the trial in the secondquarter of this year. It also will be conducted in the United Kingdom.

(c) 1997 American Health Consultants. All rights reserved.